Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.67 |
| ▸ | CDK9 | P50750 | 10/20 | 0.67 |
| ▸ | CDK4 | P11802 | 10/20 | 0.67 |
| ▸ | AURKA | O14965 | 8/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.67 |
| ▸ | CDK7 | P50613 | 7/20 | 0.67 |
| ▸ | CDK1 | P06493 | 7/20 | 0.67 |
| ▸ | WEE1 | P30291 | 2/20 | 0.63 |
| ▸ | FLT3 | P36888 | 2/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175388 | 0.91 | CDK2 (0.66) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4165980 | 0.88 | CDK2 (0.72) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4163369 | 0.88 | CDK2 (0.67) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4167251 | 0.86 | CDK2 (0.63) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4800409 | 0.85 | CDK2 (0.71) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL6156585 | 0.85 | CDK2 (0.71) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL2073844 | 0.85 | CDK2 (0.72) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4158693 | 0.84 | CDK2 (0.65) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL4168530 | 0.84 | CDK2 (0.62) | CDK2CDK9CDK4AURKAAURKB | |
| SCHEMBL2074426 | 0.83 | CDK2 (0.71) | CDK2CDK9CDK4AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-8809350-B2 | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases | CYCLACEL LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20120309723-A1 | PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | CYCLACEL LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CYCLACEL LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CYCLACEL LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | CDK2 1/4885CDK9 34/4885CDK4 2/4885 |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CDK9, SSB, CDK7 | CDK2 6/4885CDK9 1/4885CDK4 109/4885 |
| US-20120309723-A1 | PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | CDK9, CDK7, CDK2 | CDK2 3/4885CDK9 1/4885CDK4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.